SUMMARY Clobazam, 20 or 30 mg/day was given for 10 days around menstruation in successive menstrual cycles to 13 women who had responded favourably to this drug in an earlier short-term placebo controlled cross-over study. Three patients have been successfully treated, with complete freedom from seizures around menstruation, for 3-31/2 years and two others responded favourably until pregnancy made treatment inappropriate. A further four patients did well during a shorter period (6-13 months) of follow-up. An increase in seizures between periods of clobazam therapy was observed in three patients, and led to the withdrawal of this drug in two of them. However, tolerance to the antiepileptic effect of clobazam was not observed in any patient, even though nine were treated for 1 year or more. In only once case was it necessary to discontinue treatment because of sedative side effects. 
The 1-5, benzodiazepine clobazam is a potent anticonvulsant'-3 but during chronic treatment many patients develop tolerance to its antiepileptic effect.'4 After reading of the findings of Gastaut and Low' in their uncontrolled study of clobazam in chronic epilepsy, we decided to try clobazam to prevent the regular exacerbations which, even during conventional therapy, many epileptic women experience around the time of menstruation. We were able also to use catamenial epilepsy as a model in which we made a rapid evaluation of the antiepileptic effect of clobazam in a placebo controlled cross over study.2 This paper reports our long-term experience of using intermittent clobazam therapy in catamenial epilepsy. While this latter investigation took the form of an open study we have confined our observations to patients in whom we had been able to demonstrate clearly the efficacy of clobazam during the initial placebo controlled investigation. We hoped that by confining treatment to a short time (10 days) around each menstrual period we could avoid the development of tolerance to the antiepileptic effect of clobazam. only, in 13 of these women. In the case of the 14th patient who responded to clobazam it was apparent by the end of the cross-over study that, because of frequent grand mal seizures between her periods, a radical change in overall treatment was more appropriate. Our subjects were women with intractable epilepsy in whom the association of seizures with menstruation was both pronounced and consistent. In all of them, before entry to the cross-over study, it was possible to deliniate a ten-day peiniod, starting no earlier than 7 days and no later than 2 days before the menstrual flow, during which several seizures had occurred in each cycle in the preceeding six months. In both the initial cross-over study and the long term study, this ten day target period for treatment was timed for each patient so that treatment would begin two to four days before the time during which the exacerbation of epilepsy usually occurred. Subject to the unforeseeable 
Discussion
The term "catamenial epilepsy" is used to describe the association of seizure exacerbations with menstruation. It appears that many women have an increase in seizures just before and during the menses.56 Normally such women are give conventional antiepileptic therapy using drugs appropriate to their seizure types. Despite such therapy some women continue to have regular exacerbations of their epilepsy around the time of the menses. To date, treatment for this situation, using hormones, diuretics or increased doses of antiepileptics, has been largely unsatisfactory. 6 We believe that clobazam represents a valuable treatment for catamenial epilepsy. After 3-31/2 years therapy three of our 13 patients are still taking it to good effect and two others only stopped because they became pregnant. While in some other cases the duration of follow-up was inadequate to allow any firm conclusion to be drawn about the efficacy of long-term treatment the patients benefitted for many months (at least). Although it was not a prerequisite for entry to the trial, all of the women we treated had epilepsy for ten years or more and most of them had complex partial seizures which were sometimes secondarily generalised. Several drugs had been tried in all of them and despite conventional antiepileptic therapy they continued to have seizures around the time of menstruation. We believe that any therapy which proved effective in the long term in an appreciable proportion of such patients is worthwhile. We must, however, point out that we chose as our subjects women in whom the association of seizures with menstruation was both marked and consistent. Before treatment they were having two-thirds or more of all their fits around menstruation. The benefits of using clobazam might be less in women in whom the association of seizures with menstruation was less marked and/or less consistent.
Tolerance 
